1.jpg)
According to the latest research by InsightAce Analytic, the Global Longevity and Anti-Senescence Therapy Market is valued at US$ 25.33 billion in 2021, and it is expected to grow with a CAGR of 5.8% during a forecast period of 2022-2030. Longevity is an effective approach focuses on the extension of health span by slowing the rate of aging. This approach is considered as the most efficient way to combat various aging-related chronic illnesses and disabling conditions. Aging comprises a rising risk of developing a number of neurodegenerative disorders, cardiovascular disease, diabetes, osteoarthritis, and cancer, which are commonly referred to as age-related diseases (ARDs). In the recent years, the development of new interventions and rejuvenation strategies to increase health span by means of supplements and pharmaceuticals targeting aging-related pathologies are in spotlight of a new branch in geriatric medicine, geroscience. Longevity and Anti-Senescence Therapy is one of such therapy can be classified into four groups: pharmacological therapies, lifestyle related, molecular (genetic and epigenetic) and cellular.
The growing number of geriatric populations across the globe in recent years is expected to bolster demand for Longevity and Anti-Senescence Therapy Market. According to World Population Prospects 2019 (United Nations, 2019), Global population aged 65 or over was accounted for 703 Million. Globally, geriatric population is anticipated to double by 2050 to reach 1.5 billion. Increasing number of research and investment activities in the development of longevity and anti-senescence therapies is projected to positively influence the industry’s growth over the forecast period. Another key aspect including rising adoption of advanced technologies such as gene therapy, stem cell, and senolytics Drug Therapy is anticipated to trigger growth in near future. Escalating prevalence of target diseases, especially Cardiovascular Diseases, Neural Degenerative Diseases, Ophthalmology Disorders, Cancer, among the aging population is expected to assist in the growth of the market for Longevity and Anti-Senescence Therapy over the coming years.
The global Longevity and Anti-Senescence Therapy market is categorized on the basis of Therapy, Application and region. On the basis of Therapy, the market is segmented into Senolytic Drug Therapy, Gene Therapy, Cell Therapy, Mitochondrial Therapy, Immunotherapy, and Others. Based on Application the market is segmented into Longevity, Senescence Inhibition, Cardiovascular Diseases, Neural Degenerative Diseases, Ophthalmology Disorders, and Cancer. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among all, North America is expected to dominate the market during the analysis of forecast period.
The key players of this market include Acorda Therapeutics, Agex Therapeutics, Antoxerene, Calico Life Sciences, Celgene, Cleara Biotech, Human Longevity Inc., Insilico Medicine, Oisin Biotechnology, Powervision Inc., Prana Biotechnology Ltd., Proteostasis Therapeutics Inc., Recursion Pharmaceuticals, Restorbio, Sierra Sciences Llc, Senex Biotechnology, Senolytic Therapeutics, Spotlight Bioscience, T.A. Sciences, Unity Biotechnology, Alkahest, Inc., Stealth BioTherapeutics, BIOPHYTIS BSA, SIWA Therapeutics, Rejuveron Life Sciences AG, Rubedo Life Sciences, Inc, Lineage Cell Therapeutics, Juvenescence Life, Longevity Biotech CohBar, Inc. (CWBR), Genome Protection Inc., Navitor Pharmaceuticals, Inc., Elevian, Inc., Other Prominent Players.
